- Home
- FLNC vs GLUE Comparison
FLNC vs GLUE Comparison
Compare FLNC & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FLNC | GLUE |
|---|---|---|
| Founded | 2018 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FLNC | GLUE |
|---|---|---|
| Price | $21.13 | $18.92 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 3 |
| Target Price | $15.71 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 9.8M | 720.6K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,262,830,000.00 | $123,672,000.00 |
| Revenue This Year | $51.23 | N/A |
| Revenue Next Year | $21.30 | $2.45 |
| P/E Ratio | ★ N/A | $72.42 |
| Revenue Growth | N/A | ★ 63.54 |
| 52 Week Low | $4.40 | $3.84 |
| 52 Week High | $33.51 | $25.77 |
Technical Indicators
Market Signals| Indicator | FLNC | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 64.00 | 49.90 |
| Support Level | $13.05 | $18.51 |
| Resistance Level | $22.93 | $20.24 |
| Average True Range (ATR) | 2.00 | 1.05 |
| MACD | 1.07 | -0.15 |
| Stochastic Oscillator | 61.20 | 17.18 |
Price Performance
Historical ComparisonAbout FLNC Fluence Energy Inc.
Fluence Energy Inc provides intelligent energy storage and optimization software for renewables and storage. Its energy storage solutions and operational services support a more resilient grid and help unlock the potential of renewable portfolios. The company's offerings include energy storage solutions, recurring operational and maintenance services, and Software-as-a-Service (SaaS) products designed to meet customer business needs, performance requirements, in-house capabilities, and risk profiles. Its service plans offer varying levels of training, maintenance, guarantees, warranties, and support for active system management. The company operates in the Americas, APAC and EMEA, with the majority of revenue coming from the Americas.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).